As of February 2, 2026, the FDA Quality Management System Regulation (QMSR) has officially replaced the legacy QSR, mandating ISO 13485 as the non-negotiable requirement for all medical devices entering the U.S. market.
This shift signifies that quality management is no longer a “best practice”—it is a legal barrier to entry. For Medical OEMs, this requires a partner who treats quality as a molecular process, not just a checklist.
At Fenix MFG, we address these new 2026 standards through integrated Plasma Etching for Medical Reliability. Using Reactive Ion Etching (RIE) and Inductively Coupled Plasma (ICP), we modify surface energy at an atomic level. This ensures that conformal coatings on Biomedical Electronic Components achieve a permanent, hermetic-grade bond. In surgical robotics and implantable tech, this molecular integrity is the only way to prevent field failures and delamination.
By combining this technical precision with an End-to-End Box Build process under our 2025-recertified ISO 9001 and ISO 13485 frameworks, we provide a unified traceability chain. Our Clean Room Electronics environment and specialized Hi-Pot (High Potential) Testing ensure that every Medical Device Electronic component is defensive under the new, more stringent FDA inspection guidelines.
The 2026 FDA QMSR mandate has made ISO 13485 the legal standard.
At Fenix MFG, we provide the technical proof and transparency required for the next generation of life-critical devices. Partnering with Fenix ensures your product doesn’t just meet today’s regulations but survives the most demanding field conditions.
Q: Why is Plasma Etching preferred over traditional cleaning?
It removes organic impurities at the atomic level that solvents leave behind, creating a reactive surface for superior coating adhesion.
Q: Is Fenix compliant with the 2026 FDA inspection changes?
Yes. Our Cerca de la costa location facilitates the “eyes-on-production” transparency that current FDA inspection guidelines now expect.
ES 
EN